Trial Profile

A Phase 2, Open Label Study of the Safety and Effectiveness of MDMA-assisted Therapy for Participants With Posttraumatic Stress Disorder

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Methylenedioxymetamfetamine (Primary)
Indications Post-traumatic stress disorders
Focus Therapeutic Use
Acronyms NUMCAP1
Sponsors Lykos Therapeutics

Most Recent Events

27 Jan 2022 Planned End Date changed from 1 Feb 2023 to 1 Aug 2023.
27 Jan 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Aug 2023.
27 Jan 2022 Planned initiation date changed from 1 May 2022 to 1 Aug 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com